Hormonal
Semaglutide 2.4 mg subcutaneous once weekly significantly reduces body weight and improves cardiovascular risk factors in obese or overweight adults with or without type 2 diabetes.
Semaglutide 2.4 mg injected once weekly, combined with a low-calorie diet and exercise, is a highly effective treatment for weight loss and cardiovascular risk reduction in obese or overweight adults. You must commit to long-term use, as stopping the medication leads to weight regain. Start with a lower dose to minimize stomach side effects, which usually improve over time.
In all trials of the STEP program involving non-diabetic adults, the population included males or females aged at least 18 years who were overweight (a body mass index (BMI) of at least 27) with at least one related weight comorbidity (hypertension, sleep apnea, diabetes or dyslipidemia) or obese (a BMI of at least 30)... The results of the Semaglutide Treatment Effect in People with Obesity (STEP) program trials... were instrumental in the approval of this drug in this setting of patients.
Why this rating
Based on multiple large-scale randomized controlled trials (STEP 1-8, SUSTAIN) and regulatory approval.
Source
Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population
Francesco Natale et al. · Journal of Cardiovascular Development and Disease · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →